NYSE:KDMN - Kadmon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.45 +0.01 (+0.41 %)
(As of 01/18/2019 06:10 AM ET)
Previous Close$2.44
Today's Range$2.42 - $2.50
52-Week Range$1.88 - $5.86
Volume430,900 shs
Average Volume1.30 million shs
Market Capitalization$276.04 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone212-308-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.26 million
Book Value($0.49) per share

Profitability

Net Income$-79,770,000.00
Net Margins-1,176.75%

Miscellaneous

Employees101
Market Cap$276.04 million
OptionableOptionable

Kadmon (NYSE:KDMN) Frequently Asked Questions

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

How were Kadmon's earnings last quarter?

Kadmon Holdings Inc (NYSE:KDMN) released its earnings results on Friday, November, 9th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.09. The firm earned $0.37 million during the quarter, compared to the consensus estimate of $0.56 million. Kadmon had a negative return on equity of 253.82% and a negative net margin of 1,176.75%. View Kadmon's Earnings History.

When is Kadmon's next earnings date?

Kadmon is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Kadmon.

What price target have analysts set for KDMN?

4 equities research analysts have issued 1 year price targets for Kadmon's stock. Their forecasts range from $2.90 to $25.00. On average, they anticipate Kadmon's share price to reach $13.2250 in the next twelve months. This suggests a possible upside of 439.8% from the stock's current price. View Analyst Price Targets for Kadmon.

What is the consensus analysts' recommendation for Kadmon?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.

What are Wall Street analysts saying about Kadmon stock?

Here are some recent quotes from research analysts about Kadmon stock:
  • 1. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (1/17/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $25 is based on a probability adjusted sum-of-parts $12 from KD025 in cGVHD + $12 from tesevatinib in PKD + $1 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller than anticipated commercial opportunity due to market sizing, competition, and pricing. Kadmon Holdings, Inc." (11/12/2018)

Has Kadmon been receiving favorable news coverage?

News articles about KDMN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kadmon earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of Kadmon's key competitors?

Who are Kadmon's key executives?

Kadmon's management team includes the folowing people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
  • Mr. Kyle Carver, Controller & Principal Accounting Officer
  • Dr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 76)
  • Wei Chen Ph.D., Associate Director of Immunology

When did Kadmon IPO?

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Investment Advisors LLC (0.01%). Company insiders that own Kadmon stock include Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal and Steven N Gordon. View Institutional Ownership Trends for Kadmon.

Which institutional investors are buying Kadmon stock?

KDMN stock was bought by a variety of institutional investors in the last quarter, including Capital Investment Advisors LLC. Company insiders that have bought Kadmon stock in the last two years include Daniel S Loeb, Eugene Bauer, Harlan Waksal and Steven N Gordon. View Insider Buying and Selling for Kadmon.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $2.45.

How big of a company is Kadmon?

Kadmon has a market capitalization of $276.04 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is http://www.kadmon.com.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]


MarketBeat Community Rating for Kadmon (NYSE KDMN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel